167 related articles for article (PubMed ID: 36153305)
1. GOT2 consider the tumor microenvironment.
Do BT; Vander Heiden MG
Trends Cancer; 2022 Nov; 8(11):884-886. PubMed ID: 36153305
[TBL] [Abstract][Full Text] [Related]
2. A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity.
Abrego J; Sanford-Crane H; Oon C; Xiao X; Betts CB; Sun D; Nagarajan S; Diaz L; Sandborg H; Bhattacharyya S; Xia Z; Coussens LM; Tontonoz P; Sherman MH
Cancer Discov; 2022 Oct; 12(10):2414-2433. PubMed ID: 35894778
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial glutamine metabolism via GOT2 supports pancreatic cancer growth through senescence inhibition.
Yang S; Hwang S; Kim M; Seo SB; Lee JH; Jeong SM
Cell Death Dis; 2018 Jan; 9(2):55. PubMed ID: 29352139
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance.
Sherman MH; Beatty GL
Annu Rev Pathol; 2023 Jan; 18():123-148. PubMed ID: 36130070
[TBL] [Abstract][Full Text] [Related]
5. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context.
Kerk SA; Lin L; Myers AL; Sutton DJ; Andren A; Sajjakulnukit P; Zhang L; Zhang Y; Jiménez JA; Nelson BS; Chen B; Robinson A; Thurston G; Kemp SB; Steele NG; Hoffman MT; Wen HJ; Long D; Ackenhusen SE; Ramos J; Gao X; Nwosu ZC; Galban S; Halbrook CJ; Lombard DB; Piwnica-Worms DR; Ying H; Pasca di Magliano M; Crawford HC; Shah YM; Lyssiotis CA
Elife; 2022 Jul; 11():. PubMed ID: 35815941
[TBL] [Abstract][Full Text] [Related]
6. The biological underpinnings of therapeutic resistance in pancreatic cancer.
Beatty GL; Werba G; Lyssiotis CA; Simeone DM
Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
[TBL] [Abstract][Full Text] [Related]
7. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma.
Ni B; Yin Y; Li Z; Wang J; Wang X; Wang K
Neurosci Bull; 2023 Nov; 39(11):1717-1731. PubMed ID: 37347365
[TBL] [Abstract][Full Text] [Related]
9. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
Tesfaye AA; Kamgar M; Azmi A; Philip PA
Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
[TBL] [Abstract][Full Text] [Related]
10. Targeting PDAC metabolism: Environment determines what has GOT2 give.
Newsom OJ; Sullivan LB
Cell Metab; 2022 Nov; 34(11):1617-1619. PubMed ID: 36323232
[TBL] [Abstract][Full Text] [Related]
11. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
12. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment Role in Pancreatic Cancer Stem Cells.
Galindo-Vega A; Maldonado-Lagunas V; Mitre-Aguilar IB; Melendez-Zajgla J
Cells; 2023 Jun; 12(12):. PubMed ID: 37371030
[TBL] [Abstract][Full Text] [Related]
14. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
Ye C; Zheng L; Yuan CH
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
[TBL] [Abstract][Full Text] [Related]
15. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma.
Tang D; Wang D; Yuan Z; Xue X; Zhang Y; An Y; Chen J; Tu M; Lu Z; Wei J; Jiang K; Miao Y
Int J Cancer; 2013 Mar; 132(5):993-1003. PubMed ID: 22777597
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
17. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
Herting CJ; Karpovsky I; Lesinski GB
Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240
[TBL] [Abstract][Full Text] [Related]
18. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
[TBL] [Abstract][Full Text] [Related]
19. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.
Ahmad RS; Eubank TD; Lukomski S; Boone BA
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204306
[TBL] [Abstract][Full Text] [Related]
20. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma.
Chang DZ; Ma Y; Ji B; Wang H; Deng D; Liu Y; Abbruzzese JL; Liu YJ; Logsdon CD; Hwu P
Clin Cancer Res; 2011 Nov; 17(22):7015-23. PubMed ID: 21976550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
